LNAI Lunai Bioworks Inc.
Listings ·
Lunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.
Lunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.
Lunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.
The company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.
Nasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.
Lunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.
Renovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.
Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery and therapeutic development for CNS disorders, biodefense and other serious diseases. It operates principally through two subsidiaries, Renovaro Biosciences and BioSymetrics. Renovaro Biosciences intends, if the necessary funding is obtained, to develop allogeneic cell and gene therapies for certain cancers and for serious infectious diseases such as HIV. Its focus areas include RENB-DC11, a genetically modified allogeneic dendritic cell therapeutic vaccine for solid tumors, specifically pancreatic tumors, and RENB-DC20, a similar vaccine for triple negative breast cancer. BioSymetrics is a biomedical artificial intelligence company that integrates genomics, imaging, electronic health records and other real-world evidence to advance biomarker discovery and precision medicine. Its platform uses machine learning pipelines and a proprietary knowledge graph, and it collaborates with pharmaceutical companies, healthcare providers and academic institutions. A third subsidiary, Lunai Bioworks IP, Inc., holds intellectual property from the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform. The filing also says GEDi Cube B.V. filed for bankruptcy and ceased operations during the quarter ended September 30, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| RENB-DC11 | Genetically modified allogeneic dendritic cell vaccine for pancreatic tumors | completed pre-IND, IND-enabling phase |
| RENB-DC20 | Genetically modified allogeneic dendritic cell vaccine for triple negative breast cancer | |
| N2B intranasal drug delivery platform | Intranasal drug delivery platform held by Lunai Bioworks IP, Inc. | |
| BioSymetrics AI platform | Machine learning platform for biomarker discovery and precision medicine |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | $51,992 | |
| Research and development | $24,518 | $537,428 |
| Net income (loss) | -$3.6 million | -$178.0 million |
| Cash from operations | -$5.3 million | -$7.9 million |
| Cash and equivalents | $1.7 million | $92,700 |
Our latest story on this, dated Feb 12, 2026: "Lunai Bioworks receives Nasdaq delisting determination over minimum bid price, requests hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 23, 2026: "Lunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 30, 2025: "Lunai Bioworks gets Nasdaq deficiency notice on $35 million market value requirement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 13, 2026: "Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai". The story links the filing or release it is based on. Read the story.
Lunai Bioworks Inc. trades under the ticker LNAI on NASDAQ.
Lunai Bioworks Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lunai Bioworks Inc. is 1527728. Its filings are on SEC EDGAR.
5,034,452 shares as of 2026-10-13, per the cover page of its 10-K filed 2026-10-13.
Our directory records Lunai Bioworks Inc. under United States.
Our directory classifies Lunai Bioworks Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lunai Bioworks Inc. is US29350E3027.
aibio.space lists Lunai Bioworks Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery and therapeutic development for CNS disorders, biodefense and other serious diseases. It operates principally through two subsidiaries, Renovaro Biosciences and BioSymetrics.
RENB-DC11: Genetically modified allogeneic dendritic cell vaccine for pancreatic tumors Stage: completed pre-IND, IND-enabling phase.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,7.01,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.01,3.01,3.02,3.03,5.03,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a material impairment charge. SEC Form 8-K (Items 2.06,8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio